bpc-157 human trial safety If worked as well as the internet says it does… …we'd probably have high quality trials by now. Instead we have... Lots of rat studies. Lots of podcasts. Lots of Wolverine Stack: Healing Faster with

It is usually mild at the starter dose and more pronounced when the dose is escalated

clinical magnitude in humans unknown FAERS reports / Adverse event reports exist but are unverified and likely under-reported given off-label, gray-market sourcing Route-dependent risk / Injectable formulations carry sterility, endotoxin, and dosing-error risks not present with oral use Purity concern / Third-party assays on gray-market vials show batch-to-batch peptide content ranging from 60% to 110% of label claim What Is BPC-157 and Why Does Rare-but-Serious Risk Matter

This list is not exhaustive

Some health consequences might not become apparent for yearsand anecdotal evidence is rife with confounding factors